Evidence map›Paper›PMID 35675358›Full record

ArticlePLoS pathogens2022

Fibroblast growth factor-9 expression in airway epithelial cells amplifies the type I interferon response and alters influenza A virus pathogenesis.

Bradley E Hiller, Yongjun Yin, Yi-Chieh Perng, Ítalo de Araujo Castro, Lindsey E Fox, Marissa C Locke, Kristen J Monte, Carolina B López, David M Ornitz, Deborah J Lenschow

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Tropism for ciliated cells is the dominant driver of influenza viral burst size in the human airway.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Bradley E HillerDepartment of Medicine, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Yongjun YinDepartment of Developmental Biology, Washington University School of Medicine, St. Louis, Missouri, Unites States of America.
Yi-Chieh PerngDepartment of Medicine, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Ítalo de Araujo CastroDepartment of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Lindsey E FoxDepartment of Medicine, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Marissa C LockeDepartment of Medicine, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Kristen J MonteDepartment of Medicine, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Carolina B LópezDepartment of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, United States of America.
David M OrnitzDepartment of Developmental Biology, Washington University School of Medicine, St. Louis, Missouri, Unites States of America.
Deborah J LenschowDepartment of Medicine, Washington University School of Medicine, St. Louis, Missouri, United States of America.ORCID 0000-0002-9400-5309
Washington University in St. Louis · US

Funding

TRAINING PROGRAM IN IMMUNOLOGY AND IMMUNOGENETICST32AI007163 · NIAID · WASHINGTON UNIVERSITY · PI Kenneth M Murphy, Kodi S Ravichandran · 1985 to 2026
$14.8M
TRAINING IN THE IMMUNOBIOLOGY AND MOLECULAR CELL BIOLOGY OF CANCERT32CA009547 · NCI · WASHINGTON UNIVERSITY · PI ROBERT DAVID SCHREIBER · 1986 to 2026
$12.1M
Washington University Rheumatic DiseasesResearch Resource-based CenterP30AR073752 · NIAMS · WASHINGTON UNIVERSITY · PI Christine T. Pham · 2018 to 2026
$7.6M
Defective Viral genomes in RSV pathogenesisR01AI137062 · NIAID · WASHINGTON UNIVERSITY · PI Carolina B. Lopez · 2018 to 2026
$4.2M
REGULATION OF LUNG DEVELOPMENT BY FGF9 SIGNALING PATHWAYSR01HL111190 · NHLBI · WASHINGTON UNIVERSITY · PI ORNITZ, DAVID M · 2012 to 2020
$3.9M
FGF18 regulation of postnatal lung developmentR01HL154747 · NHLBI · WASHINGTON UNIVERSITY · PI ORNITZ, DAVID M · 2020 to 2023
$2.5M
Mechanisms of DDO AdjuvancyR01AI134862 · NIAID · WASHINGTON UNIVERSITY · PI LOPEZ, CAROLINA B. · 2018 to 2022
$2.4M
NCI NIH HHS T32 CA009547NHLBI NIH HHS R01 HL111190NHLBI NIH HHS R01 HL154747NIAID NIH HHS L40 AI080172NIAID NIH HHS R01 AI134862NIAID NIH HHS R01 AI137062NIAID NIH HHS T32 AI007163NIAMS NIH HHS P30 AR073752
6 · The paper itself

Abstract

Influenza A virus (IAV) preferentially infects conducting airway and alveolar epithelial cells in the lung. The outcome of these infections is impacted by the host response, including the production of various cytokines, chemokines, and growth factors. Fibroblast growth factor-9 (FGF9) is required for lung development, can display antiviral activity in vitro, and is upregulated in asymptomatic patients during early IAV infection. We therefore hypothesized that FGF9 would protect the lungs from respiratory virus infection and evaluated IAV pathogenesis in mice that overexpress FGF9 in club cells in the conducting airway epithelium (FGF9-OE mice). However, we found that FGF9-OE mice were highly susceptible to IAV and Sendai virus infection compared to control mice. FGF9-OE mice displayed elevated and persistent viral loads, increased expression of cytokines and chemokines, and increased numbers of infiltrating immune cells as early as 1 day post-infection (dpi). Gene expression analysis showed an elevated type I interferon (IFN) signature in the conducting airway epithelium and analysis of IAV tropism uncovered a dramatic shift in infection from the conducting airway epithelium to the alveolar epithelium in FGF9-OE lungs. These results demonstrate that FGF9 signaling primes the conducting airway epithelium to rapidly induce a localized IFN and proinflammatory cytokine response during viral infection. Although this response protects the airway epithelial cells from IAV infection, it allows for early and enhanced infection of the alveolar epithelium, ultimately leading to increased morbidity and mortality. Our study illuminates a novel role for FGF9 in regulating respiratory virus infection and pathogenesis.

Indexed as

Fibroblast Growth Factor 9Influenza A virusInfluenza, HumanInterferon Type IOrthomyxoviridae InfectionsAnimalsCytokinesEpithelial CellsHumansMiceCytokinesFGF9 protein, humanFgf9 protein, mouseFibroblast Growth Factor 9Interferon Type I

Identifiers

PMID35675358
PMCPMC9212157
OpenAlexW4282918857

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.